Compare OPTT & MAIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | OPTT | MAIA |
|---|---|---|
| Founded | 1984 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Electric Utilities: Central | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 76.4M | 77.1M |
| IPO Year | 2006 | 2022 |
| Metric | OPTT | MAIA |
|---|---|---|
| Price | $0.38 | $1.35 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $1.50 | N/A |
| AVG Volume (30 Days) | ★ 2.6M | 518.8K |
| Earning Date | 03-17-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 63.83 | 33.33 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $5,861,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $221.57 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 6.08 | N/A |
| 52 Week Low | $0.29 | $0.87 |
| 52 Week High | $0.90 | $3.19 |
| Indicator | OPTT | MAIA |
|---|---|---|
| Relative Strength Index (RSI) | 58.65 | 51.65 |
| Support Level | $0.38 | $1.23 |
| Resistance Level | $0.40 | $1.46 |
| Average True Range (ATR) | 0.02 | 0.08 |
| MACD | 0.01 | 0.01 |
| Stochastic Oscillator | 71.56 | 60.00 |
Ocean Power Technologies Inc provides intelligent maritime solutions and services that enable safer, cleaner, and more productive ocean operations for the defense and security, oil and gas, science and research, and offshore wind markets. It provides ocean data collection and reporting, marine power, offshore communications, and Maritime Domain Awareness System (MDAS) products, integrated solutions, and consulting services. The company offers its products and services to a wide range of customers, including those in government and offshore energy, oil and gas, construction, wind power, and other industries. The company has operations in North and South America, Europe, Asia and Australia.
MAIA Biotechnology Inc is a clinical-stage biopharmaceutical company engaged in the discovery, development, and commercialization of targeted immunotherapies for cancer, with an initial focus on non-small cell lung cancer (NSCLC), which represents the majority of lung cancer cases. Its asset, ateganosine (THIO, also known as 6-thio-dG or 6-thio-deoxyguanosine), is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. The treatment approach involves administering THIO followed by the immune checkpoint inhibitor Libtayo (cemiplimab), which is manufactured and commercialized by Regeneron.